Clinical trial of intra-arterial polychemotherapy in the treatment of carcinoma of the oral cavity.
Following studies of problems regarding the phenomenon of synchronization and cell recruitment, the authors present the results obtained using antimitotic polychemotherapy (VCR, MTX, BLM, ADM or MTC) administered to 47 patients with squamous cell carcinoma of the oral cavity. This treatment resulted in a regression in 29/47 patients (61.7 %). All patients were subjected to X-ray therapy, while only a part of the responders were subjected to surgery. Survival after 18 months from the beginning of the treatment has been 24/47 patients (51.0%). Since the majority of patients were beyond the limits of surgery and/or radiotherapy, this can be considered as a positive result, even though the risk of death due to polychemotherapy has been rather high.
D000328:Adult; D000367:Age Factors; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D001761:Bleomycin / Q000008:administration & dosage / Q000494:pharmacology; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy; D002453:Cell Cycle / Q000187:drug effects; D004317:Doxorubicin / Q000008:administration & dosage / Q000494:pharmacology; D004334:Drug Administration Schedule; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D006801:Humans; D007261:Infusions, Intra-Arterial; D008727:Methotrexate / Q000008:administration & dosage / Q000494:pharmacology; D008875:Middle Aged; D009062:Mouth Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy; D014750:Vincristine / Q000008:administration & dosage / Q000494:pharmacology
D000970:Antineoplastic Agents; D001761:Bleomycin; D014750:Vincristine; D004317:Doxorubicin; D008727:Methotrexate